Investor relations, scheme partnerships, physician network enquiries, and team opportunities. We'd love to hear from you.
Complete this form to receive the full Aafiya investor deck, including the detailed financial model, clinical validation plan, regulatory strategy, and team bios. For qualified investors and institutional partners only.
Target close Q3 2026. 20–25% dilution. 24 months to first revenue.
We are currently in conversations with medical schemes for our pilot launch (Month 19–24). Interested in being a founding scheme partner?
HPCSA-registered doctors reviewing 15–20 AI-assisted cases/hour at R110/case. Flexible, remote, and fully compliant.
We are building the founding team of 10 across engineering, clinical, and business functions. All roles are South Africa-based.
Location: Cape Town, South Africa.
Registration: Aafiya Med Pty Ltd (SA).
Data Residency: AWS Cape Town / Azure SA North.
The seed round is targeting R35–55M in total. We welcome anchor commitments of R10M+ (DFI) and individual VC commitments from R1–15M. Please use the contact form to discuss specific ticket sizes.
No. Aafiya is pre-revenue. We are in the build phase, with first medical aid revenue targeted at Month 19–24 after seed close. The seed round funds the full build-validate-launch sequence to first revenue and Series A readiness.
We have initiated SAHPRA engagement and are operating within HPCSA's Booklet 10 telemedicine framework. SAHPRA Call-Up Notices for AI clinical decision support have not yet been issued — creating a 12–18 month first-mover window for registration.
Aafiya's founding team is being assembled as part of the seed round. The platform was conceived by a multidisciplinary group with backgrounds in SA healthtech, clinical medicine, and regulatory affairs. Founding team details are included in the full investor deck.
The medical aid scheme billing model is independently viable at full scale — generating R105M+ net revenue at 480,000 annual consultations without any NHI contribution. NHI capitation is upside, not the base case.
Every AI output is reviewed and signed by an HPCSA-registered physician before reaching the patient. No autonomous AI diagnoses or prescriptions. Red-flag conditions trigger immediate emergency referral (10177). Every action has an immutable audit trail.
Per-consultation economics, revenue ramp to R182M, NHI capitation scenarios, and full cap table.
Five-layer platform design, SA-specific clinical AI, FHIR R4 infrastructure, and security posture.
HPCSA, SAHPRA, POPIA, and NHI Act — how Aafiya meets every regulatory requirement by design.